A Phase II Study of Active Immunotherapy With GRNVAC1, Autologous Mature Dendritic Cells Transfected With mRNA Encoding Human Telomerase Reverse Transcriptase, in Patients With Acute Myelogenous Leukemia in Complete Clinical Remission.

Trial Profile

A Phase II Study of Active Immunotherapy With GRNVAC1, Autologous Mature Dendritic Cells Transfected With mRNA Encoding Human Telomerase Reverse Transcriptase, in Patients With Acute Myelogenous Leukemia in Complete Clinical Remission.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs VAC 1 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Asterias Biotherapeutics; Geron Corporation
  • Most Recent Events

    • 26 Apr 2017 Results published an Asterias Biotherapeutics media release.
    • 14 Apr 2017 Results assessing feasibility, safety, immunogenicity and efficacy of hTERT, published in the Cancer
    • 10 May 2016 According to a BioTime media release, Asterias presented the data from this trial at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting on May 5, 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top